72 completed, 11 unknown, 8 recruiting, 5 terminated. 59 Not applicable, 26 Phase 2, 11 Phase 1, 3 Phase 3, 3 Phase 4.
Follow National Multiple Sclerosis Society: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis Behavioural intervention for physical activity for multiple sclerosis (BIPAMS) - Multiple Sclerosis, Relapsing-Remitting, Sexual Dysfunction | Not applicable | Not yet recruiting | University of Alabama at Birmingham | 30 | 2026-12-01 | 2025-12-22 |
| Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis NLY01, Placebo - Multiple Sclerosis | Phase 2 | Recruiting | Johns Hopkins University | 120 | 2026-04-28 | 2026-07-17 |
| Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis Perturbation Training, Treadmill Walking - Multiple Sclerosis (Relapsing Remitting) | Not applicable | Recruiting | Georgia State University | 64 | 2026-04-06 | 2026-06-17 |
| Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) Active tDCS, Sham tDCS - Multiple Sclerosis, Depression | Phase 2 | Recruiting | NYU Langone Health | 170 | 2025-08-11 | 2026-06-29 |
| FIT-ATOMIC Exercise Feasibility Trial Exercise Training, Mobility and Flexibility Training - Neuroinflammatory Diseases, Multiple Sclerosis | Not applicable | Unknown | The Hospital for Sick Children | 40 | 2025-06-01 | 2025-05-21 |
| Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis StableEyes - Multiple Sclerosis | Not applicable | Recruiting | Emory University | 138 | 2025-04-21 | 2025-07-16 |
| Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Not applicable | Recruiting | Shirley Ryan AbilityLab | 22 | 2025-02-01 | 2026-02-23 |
| Solriamfetol for the Treatment of Multiple Sclerosis Fatigue Solriamfetol, Placebo - Multiple Sclerosis, Multiple Sclerosis Fatigue | Phase 2 | Recruiting | Johns Hopkins University | 46 | 2024-06-01 | 2026-06-09 |
| A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis The Kessler Foundation modified Story Memory Technique® (KF-mSMT®), Aerobic Exercise Training (AET) plus Virtual Reality (IDEAL), Stretching and Toning (S/T) - Multiple Sclerosis | Not applicable | Recruiting | Kessler Foundation | 78 | 2024-02-12 | 2026-08-05 |
| The Neural Mechanisms of Split-belt Treadmill Adaptation in People With Multiple Sclerosis Split-belt Treadmill, Transcutaneous Electrical Nerve Stimulation (TENS) - Multiple Sclerosis | Not applicable | Completed | Colorado State University | 51 | 2023-11-28 | 2025-07-03 |
| Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study WeB, Standard pelvic floor physical therapy - Multiple Sclerosis, Urinary Bladder, Overactive | Not applicable | Active not recruiting | University of California, San Francisco | 20 | 2023-03-15 | 2026-07-08 |
| Who Benefits Most From Cognitive Rehabilitation for Multiple Sclerosis? Cognitive Rehabilitation - Multiple Sclerosis | Not applicable | Unknown | University of Nottingham | 36 | 2022-08-15 | 2022-09-09 |
| Cognitive Markers in Prodromal MS Active tDCS - Multiple Sclerosis | Not applicable | Completed | NYU Langone Health | 60 | 2022-02-09 | 2025-07-14 |
| ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis Cladribine (MAVENCLAD®), Placebo - Advanced Multiple Sclerosis, Progressive Multiple Sclerosis | Phase 2 / Phase 3 | Active not recruiting | Queen Mary University of London | 204 | 2021-06-25 | 2026-09-08 |
| Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study Multiple Sclerosis | Completed | University of Colorado, Denver | 76 | 2021-05-18 | 2024-09-25 | |
| Use of Audio Recordings of Self-Hypnosis and Meditation for Fatigue Management in Multiple Sclerosis Self-Hypnosis (HYP), Mindfulness Meditation (MM) - Multiple Sclerosis, Fatigue | Not applicable | Completed | University of Washington | 333 | 2021-04-30 | 2024-05-17 |
| ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program Physical Activity (PA) Intervention, Waitlist attention-control - Pediatric Multiple Sclerosis | Not applicable | Active not recruiting | The Hospital for Sick Children | 56 | 2020-12-01 | 2025-09-23 |
| COMPASS Study: an Online Cognitive-behavioural Therapy (CBT) Program Treating Anxiety and Low Mood in Long-term Conditions During the COVID-19 Pandemic COMPASS, Standard charity resources - Treatment of Illness-related Distress in Physical LTCs | Not applicable | Completed | King's College London | 194 | 2020-11-16 | 2022-03-31 |
| Development of a Telehealth Obesity Intervention for Patients With MS: Modifying Diet and Exercise in MS behavioral telehealth, Treatment as Usual - Multiple Sclerosis, Obesity | Not applicable | Completed | Jared Bruce | 70 | 2020-08-01 | 2023-11-30 |
| Waking Hypnosis in the Treatment of MS-related Fatigue Active-Alert Hypnosis, Traditional Hypnosis - Multiple Sclerosis | Not applicable | Completed | University of Washington | 32 | 2020-05-27 | 2021-05-03 |
Showing 20 of 102. Sign in to see all of them.
Multiple Sclerosis (91) · Fatigue (15) · Multiple Sclerosis, Relapsing-Remitting (12) · Motor Activity (9) · Multiple Sclerosis, Chronic Progressive (6) · Demyelinating Diseases (4) · Chronic Pain (3) · Cognitive Dysfunction (3) · Depression (3) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Dizziness (2) · Pain (2) · Agnosia (1) · Autoimmune Diseases (1)
Exercise (7) · Cognitive Behavioral Therapy (3) · Glatiramer Acetate (3) · Aspirin (2) · Cladribine (2) · Constraint Induced Movement Therapy (2) · Hypnosis (2) · Interferon beta-1a (2) · Modafinil (2) · Riluzole (2) · Sugars (2) · ocrelizumab (2) · ASP-1 protein, Necator americanus (1) · Alemtuzumab (1) · Amiloride (1)
United States (87) · United Kingdom (9) · Canada (6) · Germany (2) · New Zealand (1) · Switzerland (1)
Bardia Nourbakhsh, MD, MAS (2) · Dawn Ehde, PhD (2) · Ellen M Mowry, MD, MCR (2) · Jared Bruce, PhD (2) · John Corboy, MD (2) · Leigh Charvet, MD (2) · Mark Jensen, Ph.D. (2) · Nancy Chiaravalloti, PhD (2) · Rhonda Voskuhl, M.D. (2) · Victor W Mark, MD (2) · Victoria M Leavitt, PhD (2) · Abbey Hughes, PhD (1) · Alison Luckey (1) · Anne Cross, M.D. (1) · Anthony Reder, M.D. (1)
PMID 16126743, PMID 17058754, PMID 17438241, PMID 17502467, PMID 17765329, PMID 18507817, PMID 18671877, PMID 19833477, PMID 20803391, PMID 21104484, PMID 21282661, PMID 21372112, PMID 21387374, PMID 21680771, PMID 21803872, PMID 21978993, PMID 22805247, PMID 23072517, PMID 23800444, PMID 24120943, PMID 24287594, PMID 24634831, PMID 24687904, PMID 25448627, PMID 25929276, PMID 26563147, PMID 26621682, PMID 26822749, PMID 27717498, PMID 28148632, PMID 28273780, PMID 28393317, PMID 28485659, PMID 28493924, PMID 28607691, PMID 28978801, PMID 29064315, PMID 29177070, PMID 29274015, PMID 29275977, PMID 29386274, PMID 29668399, PMID 29668401, PMID 29866196, PMID 29911511, PMID 30157388, PMID 30166303, PMID 30211252, PMID 30821692, PMID 30878208
2018 (1), R01NS051591 (1), U01NS082329 (1)